Peptide Therapeutics Market Size, Share & Industry Analysis, By Product Type (Generic, Innovative (Patented)), By Route of Administration (Parenteral, Oral, Nasal), By Application (Central Nervous System Disorders, Respiratory Disorders, Metabolic Disorder, Allergy/Immunological), By End-user (Pharmaceutical & Biotechnology Industries, Academic & Research Institutes, Contract Research Organization) and Regional Forecast, 2024-2032

Peptides and proteins are the major building blocks of life and are one of the promising therapeutics targeting a wide variety of diseases. Growing demand for protein-based drugs has led to rapid growth in the development of therapeutic proteins over the past decade. Most of the peptides in the clinical trial are used for addressing various indications such as cancer, cardiovascular disease, respiratory disorders, metabolic disorders, central nervous disease, etc.

Peptide therapeutics offers several advantages as they manifest increased potency & selectivity is anticipated to fuel the demand for peptide therapeutics in the forthcoming years. Growing investments in drug development domain by many key players to introduce innovative peptide drugs and the growing prevalence of metabolic diseases & cancer are likely to boost the peptide therapeutics market growth during the forecast period.

Along with this, growing product launches by many key players through strategic partnerships and acquisitions is anticipated to expand the peptide therapeutics market during the forecast period. For instance, in 2018, Boston Therapeutics, strengthened its product portfolio by adding pipeline peptide drug HIP2B through the strategic acquisition of CureDM, Inc. The peptide molecule will be used for the treatment of type 2 diabetes by enhancing insulin rates, which is likely to augment the peptide therapeutics market growth during the forecast period.

Peptide Therapeutics Industry Overview:

Growing prevalence of chronic diseases, increased geriatric patient population, and growing investments in research & development sector by many key players & government organizations are anticipated to drive the peptide therapeutics market growth during the forecast period. Rapidly growing technological advancements in improving the automation process & purity and rising awareness about the growing application of peptides in the treatment of various diseases are likely to boost the peptide therapeutics market during the forecast period.

However, the easy degradation of peptide molecules due to their short-half life is likely to hinder the peptide therapeutics market growth during the forecast period.

Key Players Covered

Some of the major companies that are present in the global peptide therapeutics market are Bachem Holding AG, Eli Lilly, and Company, Pfizer Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, Lonza Inc., Sanofi S.A., Bristol-Myers Squibb (BMS), AstraZeneca, and others

Segmentation

Among product type, innovative peptide therapeutics segment is anticipated to hold the largest share of peptide therapeutics market during the forecast period owing to the high cost of these products increase in the unmet needs to treat various chronic diseases

Key Insights

• Overview of Technological Advancements in Peptide Synthesis


• The Regulatory Scenario for Key Countries/Regions


• Pipeline Analysis


• New Product Approvals


• Overview of The Prevalence of Chronic Disorders- Key Countries 2018


• Key Industry Developments Mergers, Partnership, And Acquisitions

 Regional Analysis

Geographically, the global peptide therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East Asia and Africa. North America is anticipated to dominate the global peptide therapeutics market owing to the presence of many pharmaceutical players, increased research work in proteomics & genomics sector, and growing investments by key players in developing innovative peptide drug molecules. In Europe, increasing awareness about the applications of peptide for the treatment of various chronic diseases is likely to boost the peptide therapeutics market growth during the forecast period. In the Asia Pacific is peptide therapeutics market is anticipated to grow at a significant rate owing to the growing patient population and the presence of many key players involved in life science research.

Key Industry Developments

• In June 2019, PeptiDream Inc. and Novartis AG signed new Peptide Drug Conjugate “PDC” collaboration agreement to initiate macro cyclic peptide discovery, which will be used to address therapeutic and diagnostic application.


• In June 2019, Boehringer Ingelheim International GmbH announced its collaboration with Gubra for the development of novel poly-agonist peptides to treat obesity.


• In March 2019, Alexion Pharmaceuticals, Inc. collaborate with Zealand Pharma A/S with the goal to discover and develop peptide therapies subcutaneously delivered peptide therapies directed to up to four complement pathway targets.


• In August 2019, Aquinox Pharmaceuticals, Inc. and Neoleukin Therapeutics, Inc. entered into mergers agreement with an aim to develop and commercialize Computationally-designed protein therapeutics to address significant unmet medical needs in immuno-oncology, inflammation, and autoimmunity.